Pharma Equity Group AS (OCSE:PEG) Cash-to-Debt : 0.07 (As of Sep. 2024)

View and export this data going back to 2003. Start your Free Trial

What is Pharma Equity Group AS Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Pharma Equity Group AS's cash to debt ratio for the quarter that ended in Sep. 2024 was 0.07.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Pharma Equity Group AS couldn't pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

The historical rank and industry rank for Pharma Equity Group AS's Cash-to-Debt or its related term are showing as below:

OCSE:PEG' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.09 Max: 1.73
Current: 0.07

During the past 13 years, Pharma Equity Group AS's highest Cash to Debt Ratio was 1.73. The lowest was 0.00. And the median was 0.09.

OCSE:PEG's Cash-to-Debt is ranked worse than
95.63% of 1487 companies
in the Biotechnology industry
Industry Median: 6.38 vs OCSE:PEG: 0.07

Pharma Equity Group AS Cash-to-Debt Historical Data

The historical data trend for Pharma Equity Group AS's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Pharma Equity Group AS Cash-to-Debt Chart

Pharma Equity Group AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

0.01

0.14

Pharma Equity Group AS Quarterly Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															0.07	0.14	0.06	0.02	0.07

Competitive Comparison of Pharma Equity Group AS's Cash-to-Debt

For the Biotechnology subindustry, Pharma Equity Group AS's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharma Equity Group AS's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharma Equity Group AS's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Pharma Equity Group AS's Cash-to-Debt falls into.

Pharma Equity Group AS Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Pharma Equity Group AS's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	4.231	/	(22.149	+	8.072)
	=	0.14

Pharma Equity Group AS's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	3.77	/	(32.384	+	20.302)
	=	0.07

Pharma Equity Group AS (OCSE:PEG) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Pharma Equity Group AS Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Pharma Equity Group AS's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharma Equity Group AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Equity Group AS (OCSE:PEG) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Slotsmarken 18, 2.th., Horsholm, DNK, DK-2970

Website

https://www.pharmaequitygroup.com

Pharma Equity Group AS is an investment company specializing in the life science industry. The group is focused on an early investment in various life science companies that develop technologies and therapies that have the potential to improve human health and quality of life. The group specializes in early-stage investments in biotechnology, that are developing novel therapies for unmet medical needs. Its portfolio consists of companies dedicated to developing novel, effective treatments for diseases with patient and social impact for which current therapy is lacking or in need of improvement. Its drug candidates include RNX-011, RNX-021, RNX-022, RNX-023, RNX-041, and RNX-051 .